Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tyldesley

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Current Oncology (Toronto, Ont.)|December 31, 2020
Presenting stage and risk group in men dying of prostate cancerS Parimi, S Bondy, M Aparicio, et al.
Australasian Radiology|December 31, 1997
Percutaneous gastrostomy in radiologic practiceP L Munk, M J Lee, P Y Poon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2010
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapiesC Kollmannsberger, S Tyldesley, C Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breastA C Lo, P T Truong, E S Wai, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapyA Fong, J Shafiq, C Saunders, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 3, 2026
Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 TrialT Kunkyab, D Hyde, B Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 2022
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 TrialS Baker, B Mou, W Jiang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 31, 2024
Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II TrialE M Cruz-Lim, B Mou, W Jiang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 13, 2023
Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II TrialE M Cruz-Lim, B Mou, S Baker, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Current Oncology (Toronto, Ont.)|December 31, 2020
Presenting stage and risk group in men dying of prostate cancerS Parimi, S Bondy, M Aparicio, et al.
Australasian Radiology|December 31, 1997
Percutaneous gastrostomy in radiologic practiceP L Munk, M J Lee, P Y Poon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2010
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapiesC Kollmannsberger, S Tyldesley, C Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breastA C Lo, P T Truong, E S Wai, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapyA Fong, J Shafiq, C Saunders, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 3, 2026
Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 TrialT Kunkyab, D Hyde, B Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|October 27, 2022
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 TrialS Baker, B Mou, W Jiang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 31, 2024
Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II TrialE M Cruz-Lim, B Mou, W Jiang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 13, 2023
Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II TrialE M Cruz-Lim, B Mou, S Baker, et al.
Pageof 3